3 results match your criteria: "Agora Research Center[Affiliation]"
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.
Nature
January 2025
Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
The tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses. Within the tumour microenvironment, CD8 T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions in specialized niches. Although interactions with type 1 conventional dendritic cells have been implicated in this process, the underlying cellular players and molecular mechanisms remain incompletely understood.
View Article and Find Full Text PDFPD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
J Immunother Cancer
October 2023
President, ETOP IBCSG Partners Foundation, Bern, Switzerland.
Article Synopsis
- Current biomarkers for selecting cancer patients for PD-1 inhibitors, like PD-L1 expression, are often unreliable, particularly in malignant pleural mesothelioma, prompting a search for more effective markers.
- In a study involving 144 patients, researchers analyzed immune cells in tumors to determine their relationship with treatment outcomes and discovered that traditional markers like total CD8+ T cells and macrophage presence did not predict patient survival benefits.
- The study revealed that the presence of PD-1-expressing CD8+ T cells and PD-1-expressing macrophages is an independent predictor of progression-free survival, indicating their potential as valuable biomarkers for immunotherapy success.
Editorial: Immunopeptidomic Approaches for the Identification of Tumor (neo)Antigens.
Front Immunol
June 2022
Ludwig Institute for Cancer Research, Lausanne, Agora Research Center, Lausanne, Switzerland.